Smoldering Multiple Myeloma: Who and when to treat

Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder characterized by the presence of ≥ 3 g/dL serum M-protein and/or 10-60% bone marrow plasma cell infiltration with no myeloma-defining event. The risk of progression to active MM is not uniform, and several markers are useful for identifying patients at high risk of progression. The definition of the disease has recently been revi sited and asymptomatic MMs at 80-90% of progression risk at 2 years are now considered to be active MMs candidates for treatment.

Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Mar ía-Victoria Mateos, Verónica González-Calle Tags: Review Article Source Type: research